[Use of piperacillin-tazobactam in abdominal surgery].
Piperacillin/tazobactam (P/T) was used in the monotherapy of 40 patients with various inflammatory diseases of the abdominal cavity organs. P/T was administered as dropwise intravenous infusions in a single dose of 4/0.5 g 3 times a day for 5 to 17 days. In 82.5 per cent of the patients with infection of the abdominal cavity: severe postoperative purulent wounds, peritonitis of various etiology (biliary, serous-fibrinous, hemorrhagic fibrinous), postnecrotic cyst of the pancrease, abscesses of the liver and subhepatic space P/T proved to be highly efficient. The P/T monotherapy resulted in practically complete eradication of anaerobic microbes, coagulase negative staphylococci, enterobacteria and nonfermenting bacteria except for Pseudomonas aeruginosa in the inflammation foci.
Savov
A M
AM
Savitskaia
K I
KI
Lobakov
A I
AI
Klimonova
N V
NV
Nasonov
V N
VN
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use*; D010538:Peritonitis / Q000188:drug therapy; D010878:Piperacillin / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy; D000078142:Tazobactam; D016896:Treatment Outcome; D065093:beta-Lactamase Inhibitors
D004791:Enzyme Inhibitors; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin